雷替曲塞联合吉西他滨治疗晚期乳腺癌的临床观察

目的:观察雷替曲塞联合吉西他滨治疗晚期乳腺癌的临床疗效和安全性。方法:76例晚期乳腺癌患者按随机数字表法均分为试验组和对照组。试验组患者以雷替曲塞3 mg/m2加入0.9%氯化钠注射液300 ml中,于d1静脉滴注,并以吉西他滨1 000 mg/m2加入0.9%氯化钠注射液300 ml中,于d1、d8静脉滴注;对照组患者以氟尿嘧啶500 mg/m2加入0.9%氯化钠注射液300ml中,于d1-5静脉滴注,并以吉西他滨1 000 mg/m2加入0.9%氯化钠注射液300 ml中,于d1、d8静脉滴注。两组均21 d为1个周期,2个周期后判定疗效。比较两组患者的临床疗效、毒性反应及随访1年后的生存率。结果:两组患者总有效率比较,差异无统计学意义(P>0.05);试验组患者发生呕吐、发热、腹泻、呼吸困难的例数显著低于对照组,两组比较差异均有统计学意义(P<0.05);试验组患者1年后的生存率显著高于对照组,两组比较差异有统计学意义(P<0.05)。结论:雷替曲塞联合吉西他滨治疗晚期乳腺癌具有较好的疗效和安全性。

Clinical Observation of Raltitrexed Combined with Gemcitabine in the Treatment of Advanced Breast Cancer

OBJECTIVE： To observe the clinical efficacy and safety of raltitrexed combined with gemcitabine in the treatment of advanced breast cancer. METHODS： 76 patients with advanced breast cancer in our hospital were randomly divided into trial group and control group. Trial group was given raltitrexed 3 mg/m2 added into 0.9% NaC1 300 ml on the 1st day, and gemcitabine 1 000 mg/m2 added into 0.9% NaC1 300 ml intravenously on the 1st and 8th day. Control group was given fluorouracil 500 mg/m2 added into 0.9% NaC1 300mL during the 1st to 5th day, then gemcitabine 1 000 mg/m2 added into0.9% NaC1 300 ml intravenously on the 1st and 8th day. A treatment cycle lasted for 21 days, and therapeutic efficacy was evaluated after 2 cycles. Clinical efficacies of 2 groups were observed, and toxic reaction and survival rate after one year follow-up were also observed. RESULTS ： There was no statistical significance in total effective rate of 2 groups （P〉0.05）. The case number of vomiting, fever, diarrhea, dyspnea of trial group were significantly lower than in control group; there were statistical significance （P〈0.05）. The survival rate of trial group was significantly higher than that of control group; there was statistical significance （P〈0.05）. CONCLUSIONS： It has bet- ter efficacy and safety that applying raltitrexed combined with gemcitabine in the treatment of advanced breast cancer.